Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA
Identification of clinical and genetic biomarkers for recurrence risk prediction in resected melanoma may aid in clinical decision-making for early disease monitoring and optimal design of therapeutic strategies.
Authors
- Kelin Zheng
- Yu Ren (ORCID: https://orcid.org/0000-0002-6399-5493)
- Fufeng Wang (ORCID: https://orcid.org/0000-0002-8933-4909)
- Xinyu Su (ORCID: https://orcid.org/0000-0003-1890-8810)
- Yirong Wu (ORCID: https://orcid.org/0000-0002-4364-8654)
- Zhengyun Zou (ORCID: https://orcid.org/0000-0002-8719-6135)
- Luqiao Li
- Yueling Yang (ORCID: https://orcid.org/0000-0002-7688-2076)
- Jiani C. Yin (ORCID: https://orcid.org/0000-0002-9523-1930)
- Jiayu Wang (ORCID: https://orcid.org/0000-0003-2509-4579)
- Lianjun Zhao
- Rong Huang (ORCID: https://orcid.org/0000-0002-4062-717X)
- Xiaoying Wu (ORCID: https://orcid.org/0000-0002-5486-9938)
- Mengke Zhao
Institutions
- Nanjing University of Chinese Medicine (CN)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1186/s12885-025-15093-w
- Citations
- 1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province